Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Debt to Equity (2016)

Historic Debt to Equity for Gyre Therapeutics (GYRE) over the last 8 years, with Q3 2016 value amounting to $0.0.

  • Gyre Therapeutics' Debt to Equity fell 9235.03% to $0.0 in Q3 2016 from the same period last year, while for Sep 2016 it was $0.0, marking a year-over-year decrease of 9235.03%. This contributed to the annual value of $0.04 for FY2015, which is N/A changed from last year.
  • As of Q3 2016, Gyre Therapeutics' Debt to Equity stood at $0.0, which was down 9235.03% from $0.01 recorded in Q2 2016.
  • In the past 5 years, Gyre Therapeutics' Debt to Equity registered a high of $0.04 during Q4 2015, and its lowest value of -$0.02 during Q4 2012.
  • For the 5-year period, Gyre Therapeutics' Debt to Equity averaged around $0.01, with its median value being $0.01 (2014).
  • As far as peak fluctuations go, Gyre Therapeutics' Debt to Equity plummeted by 21497.37% in 2012, and later surged by 34102.87% in 2015.
  • Over the past 5 years, Gyre Therapeutics' Debt to Equity (Quarter) stood at -$0.02 in 2012, then soared by 48.19% to -$0.01 in 2013, then skyrocketed by 138.39% to $0.0 in 2014, then skyrocketed by 768.93% to $0.04 in 2015, then tumbled by 96.12% to $0.0 in 2016.
  • Its Debt to Equity stands at $0.0 for Q3 2016, versus $0.01 for Q2 2016 and $0.01 for Q1 2016.